Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran AMG 890 (a GalNAc-conjugated Small Interfering RNA [siRNA]) in Subjects with Elevated Lipoprotein(a)

Next Previous
Trial Profile

A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran AMG 890 (a GalNAc-conjugated Small Interfering RNA [siRNA]) in Subjects with Elevated Lipoprotein(a)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olpasiran (Primary)
  • Indications Atherosclerosis; Cardiovascular disorders
  • Focus Biomarker; Therapeutic Use
  • Acronyms OCEAN(a)-DOSE
  • Sponsors Amgen

Most Recent Events

  • 15 Nov 2023 According to an Amgen media release, data from the study will be presented at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia.
  • 13 Nov 2023 Results assessing intraindividual variability in Lp(a) concentration, presented at the American Heart Association Scientific Sessions 2023
  • 26 Aug 2023 Results published in an Amgen media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top